{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T07:00:13Z","timestamp":1792738813600,"version":"4.5.0"},"reference-count":103,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T00:00:00Z","timestamp":1738627200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T00:00:00Z","timestamp":1738627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","award":["U54-CA209988"],"award-info":[{"award-number":["U54-CA209988"]}]},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","award":["P30CA069533"],"award-info":[{"award-number":["P30CA069533"]}]},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","award":["T32CA254888"],"award-info":[{"award-number":["T32CA254888"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Paclitaxel is a standard of care neoadjuvant therapy for patients with triple negative breast cancer (TNBC); however, it shows limited benefit for locally advanced or metastatic disease. Here we used a coordinated experimental-computational approach to explore the influence of paclitaxel on the cellular and molecular responses of TNBC cells. We found that escalating doses of paclitaxel resulted in multinucleation, promotion of senescence, and initiation of DNA damage induced apoptosis. Single-cell RNA sequencing (scRNA-seq) of TNBC cells after paclitaxel treatment revealed upregulation of innate immune programs canonically associated with interferon response and downregulation of cell cycle progression programs. Systematic exploration of transcriptional responses to paclitaxel and cancer-associated microenvironmental factors revealed common gene programs induced by paclitaxel, IFNB, and IFNG. Transcription factor (TF) enrichment analysis identified 13 TFs that were both enriched based on activity of downstream targets and also significantly upregulated after paclitaxel treatment. Functional assessment with siRNA knockdown confirmed that the TFs FOSL1, NFE2L2 and ELF3 mediate cellular proliferation and also regulate nuclear structure. We further explored the influence of these TFs on paclitaxel-induced cell cycle behavior via live cell imaging, which revealed altered progression rates through G1, S\/G2 and M phases. We found that ELF3 knockdown synergized with paclitaxel treatment to lock cells in a G1 state and prevent cell cycle progression. Analysis of publicly available breast cancer patient data showed that high ELF3 expression was associated with poor prognosis and enrichment in programs associated with cell cycle progression. Together these analyses disentangle the diverse aspects of paclitaxel response and identify ELF3 upregulation as a putative biomarker of paclitaxel resistance in TNBC.<\/jats:p>","DOI":"10.1038\/s41598-024-82218-9","type":"journal-article","created":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T15:38:27Z","timestamp":1738683507000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["TNBC response to paclitaxel phenocopies interferon response which reveals cell cycle-associated resistance mechanisms"],"prefix":"10.1038","volume":"15","author":[{"given":"Nicholas L.","family":"Calistri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiera A.","family":"Liby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Dane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean M.","family":"Gross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura M.","family":"Heiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,4]]},"reference":[{"issue":"9","key":"82218_CR1","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1002\/cncr.22618","volume":"109","author":"KR Bauer","year":"2007","unstructured":"Bauer, K. R. et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype. Cancer 109(9), 1721\u20131728 (2007).","journal-title":"Cancer"},{"issue":"9814","key":"82218_CR2","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/S0140-6736(11)61625-5","volume":"379","author":"Early Breast Cancer Trialists\u2019 Collaborative Group","year":"2012","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group. Comparisons between different polychemotherapy regimens for early breast cancer: Meta-analyses of long-term outcome among 100 000 women in 123 randomised trials. The Lancet 379(9814), 432\u2013444 (2012).","journal-title":"The Lancet"},{"key":"82218_CR3","doi-asserted-by":"publisher","first-page":"4303","DOI":"10.2147\/DDDT.S86105","volume":"9","author":"G Mustacchi","year":"2015","unstructured":"Mustacchi, G. & De Laurentiis, M. The role of taxanes in triple-negative breast cancer: Literature review. Drug Des. Dev. Ther. 9, 4303 (2015).","journal-title":"Drug Des. Dev. Ther."},{"issue":"12","key":"82218_CR4","doi-asserted-by":"publisher","first-page":"789","DOI":"10.3390\/biom9120789","volume":"9","author":"TM Abu Samaan","year":"2019","unstructured":"Abu Samaan, T. M. et al. Paclitaxel\u2019s mechanistic and clinical effects on breast cancer. Biomolecules 9(12), 789 (2019).","journal-title":"Biomolecules"},{"issue":"12","key":"82218_CR5","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.1158\/1535-7163.MCT-21-0195","volume":"20","author":"Y Hu","year":"2021","unstructured":"Hu, Y. et al. Paclitaxel induces micronucleation and activates pro-inflammatory cGAS-STING signaling in triple-negative breast cancer. Mol. Cancer Ther. 20(12), 2553\u20132567 (2021).","journal-title":"Mol. Cancer Ther."},{"issue":"4","key":"82218_CR6","first-page":"86","volume":"2","author":"ER Smith","year":"2021","unstructured":"Smith, E. R. & Xu, X. X. Breaking malignant nuclei as a non-mitotic mechanism of taxol\/paclitaxel. J. Cancer Biol. 2(4), 86\u201393 (2021).","journal-title":"J. Cancer Biol."},{"issue":"10","key":"82218_CR7","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1200\/JCO.22.02572","volume":"41","author":"C Liedtke","year":"2023","unstructured":"Liedtke, C. et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J. Clin. Oncol. 41(10), 1809\u20131815 (2023).","journal-title":"J. Clin. Oncol."},{"issue":"20","key":"82218_CR8","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1056\/NEJMra1001389","volume":"363","author":"WD Foulkes","year":"2010","unstructured":"Foulkes, W. D., Smith, I. E. & Reis-Filho, J. S. Triple-negative breast cancer. N. Engl. J. Med. 363(20), 1938\u20131948 (2010).","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"82218_CR9","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","volume":"379","author":"P Schmid","year":"2018","unstructured":"Schmid, P. et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N. Engl. J. Med. 379(22), 2108\u20132121 (2018).","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"82218_CR10","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/s41568-022-00454-5","volume":"22","author":"M Labrie","year":"2022","unstructured":"Labrie, M. et al. Therapy resistance: Opportunities created by adaptive responses to targeted therapies in cancer. Nat. Rev. Cancer 22(6), 323\u2013339 (2022).","journal-title":"Nat. Rev. Cancer"},{"issue":"7","key":"82218_CR11","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1158\/1078-0432.CCR-14-0432","volume":"21","author":"MD Burstein","year":"2015","unstructured":"Burstein, M. D. et al. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin. Cancer Res. 21(7), 1688\u20131698 (2015).","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"82218_CR12","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/nrc.2017.117","volume":"18","author":"S Spranger","year":"2018","unstructured":"Spranger, S. & Gajewski, T. F. Impact of oncogenic pathways on evasion of antitumour immune responses. Nat. Rev. Cancer 18(3), 139\u2013147 (2018).","journal-title":"Nat. Rev. Cancer"},{"issue":"5","key":"82218_CR13","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.trecan.2020.10.010","volume":"7","author":"KE Baillie","year":"2021","unstructured":"Baillie, K. E. & Stirling, P. C. Beyond kinases: Targeting replication stress proteins in cancer therapy. Trends Cancer 7(5), 430\u2013446 (2021).","journal-title":"Trends Cancer"},{"issue":"5","key":"82218_CR14","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.trecan.2019.02.010","volume":"5","author":"CDK Nguyen","year":"2019","unstructured":"Nguyen, C. D. K. & Yi, C. YAP\/TAZ signaling and resistance to cancer therapy. Trends Cancer 5(5), 283\u2013296 (2019).","journal-title":"Trends Cancer"},{"issue":"12","key":"82218_CR15","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1038\/s41556-018-0236-7","volume":"20","author":"DA Lawson","year":"2018","unstructured":"Lawson, D. A. et al. Tumour heterogeneity and metastasis at single-cell resolution. Nat. Cell Biol. 20(12), 1349\u20131360 (2018).","journal-title":"Nat. Cell Biol."},{"issue":"11","key":"82218_CR16","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1038\/nmeth.4463","volume":"14","author":"S Aibar","year":"2017","unstructured":"Aibar, S. et al. SCENIC: Single-cell regulatory network inference and clustering. Nat. Methods 14(11), 1083\u20131086 (2017).","journal-title":"Nat. Methods"},{"issue":"11","key":"82218_CR17","doi-asserted-by":"publisher","first-page":"2988","DOI":"10.1016\/j.cell.2021.04.038","volume":"184","author":"A Obradovic","year":"2021","unstructured":"Obradovic, A. et al. Single-cell protein activity analysis identifies recurrence-associated renal tumor macrophages. Cell 184(11), 2988-3005 e16 (2021).","journal-title":"Cell"},{"issue":"6","key":"82218_CR18","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/nmeth.3853","volume":"13","author":"M Hafner","year":"2016","unstructured":"Hafner, M. et al. Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs. Nat. Methods 13(6), 521\u2013527 (2016).","journal-title":"Nat. Methods"},{"issue":"18","key":"82218_CR19","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1091\/mbc.e14-04-0916","volume":"25","author":"BA Weaver","year":"2014","unstructured":"Weaver, B. A. How Taxol\/paclitaxel kills cancer cells. Mol. Biol. Cell 25(18), 2677\u20132681 (2014).","journal-title":"Mol. Biol. Cell"},{"issue":"4","key":"82218_CR20","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1111\/j.1365-2559.2007.02792.x","volume":"51","author":"KM Lee","year":"2007","unstructured":"Lee, K. M. et al. Class III \u03b2-tubulin, a marker of resistance to paclitaxel, is overexpressed in pancreatic ductal adenocarcinoma and intraepithelial neoplasia. Histopathology 51(4), 539\u2013546 (2007).","journal-title":"Histopathology"},{"issue":"2","key":"82218_CR21","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/sj.bjc.6605489","volume":"102","author":"C Stengel","year":"2010","unstructured":"Stengel, C. et al. Class III beta-tubulin expression and in vitro resistance to microtubule targeting agents. Br. J. Cancer 102(2), 316\u2013324 (2010).","journal-title":"Br. J. Cancer"},{"key":"82218_CR22","doi-asserted-by":"publisher","first-page":"33123","DOI":"10.1038\/srep33123","volume":"6","author":"KV Sawant","year":"2016","unstructured":"Sawant, K. V. et al. Chemokine CXCL1 mediated neutrophil recruitment: Role of glycosaminoglycan interactions. Sci. Rep. 6, 33123 (2016).","journal-title":"Sci. Rep."},{"issue":"3","key":"82218_CR23","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41423-023-00974-6","volume":"20","author":"S Cambier","year":"2023","unstructured":"Cambier, S., Gouwy, M. & Proost, P. The chemokines CXCL8 and CXCL12: Molecular and functional properties, role in disease and efforts towards pharmacological intervention. Cell Mol. Immunol. 20(3), 217\u2013251 (2023).","journal-title":"Cell Mol. Immunol."},{"key":"82218_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.723846","volume":"9","author":"X Xiong","year":"2022","unstructured":"Xiong, X. et al. CXCL8 in tumor biology and its implications for clinical translation. Front. Mol. Biosci. 9, 723846 (2022).","journal-title":"Front. Mol. Biosci."},{"issue":"9","key":"82218_CR25","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1038\/s41419-018-0876-3","volume":"9","author":"N Wang","year":"2018","unstructured":"Wang, N. et al. CXCL1 derived from tumor-associated macrophages promotes breast cancer metastasis via activating NF-kappaB\/SOX4 signaling. Cell Death Dis. 9(9), 880 (2018).","journal-title":"Cell Death Dis."},{"issue":"1","key":"82218_CR26","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1038\/s42003-022-03975-9","volume":"5","author":"SM Gross","year":"2022","unstructured":"Gross, S. M. et al. A multi-omic analysis of MCF10A cells provides a resource for integrative assessment of ligand-mediated molecular and phenotypic responses. Commun. Biol. 5(1), 1066 (2022).","journal-title":"Commun. Biol."},{"key":"82218_CR27","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.canlet.2019.07.012","volume":"461","author":"BM Krishna","year":"2019","unstructured":"Krishna, B. M. et al. Notch signaling in breast cancer: From pathway analysis to therapy. Cancer Lett. 461, 123\u2013131 (2019).","journal-title":"Cancer Lett."},{"issue":"12","key":"82218_CR28","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.3390\/cancers11121943","volume":"11","author":"E Arico","year":"2019","unstructured":"Arico, E. et al. Type I interferons and cancer: An evolving story demanding novel clinical applications. Cancers (Basel) 11(12), 1943 (2019).","journal-title":"Cancers (Basel)"},{"key":"82218_CR29","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s40364-020-00228-x","volume":"8","author":"D Jorgovanovic","year":"2020","unstructured":"Jorgovanovic, D. et al. Roles of IFN-gamma in tumor progression and regression: A review. Biomark. Res. 8, 49 (2020).","journal-title":"Biomark. Res."},{"issue":"3","key":"82218_CR30","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.cell.2009.06.015","volume":"138","author":"YH Chiu","year":"2009","unstructured":"Chiu, Y. H., Macmillan, J. B. & Chen, Z. J. RNA polymerase III detects cytosolic DNA and induces type I interferons through the RIG-I pathway. Cell 138(3), 576\u2013591 (2009).","journal-title":"Cell"},{"issue":"1","key":"82218_CR31","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41392-021-00554-y","volume":"6","author":"L Yu","year":"2021","unstructured":"Yu, L. & Liu, P. Cytosolic DNA sensing by cGAS: Regulation, function, and human diseases. Signal Transduct. Target Ther. 6(1), 170 (2021).","journal-title":"Signal Transduct. Target Ther."},{"issue":"W1","key":"82218_CR32","doi-asserted-by":"publisher","first-page":"W212","DOI":"10.1093\/nar\/gkz446","volume":"47","author":"AB Keenan","year":"2019","unstructured":"Keenan, A. B. et al. ChEA3: Transcription factor enrichment analysis by orthogonal omics integration. Nucleic Acids Res. 47(W1), W212\u2013W224 (2019).","journal-title":"Nucleic Acids Res."},{"key":"82218_CR33","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jbior.2016.05.001","volume":"62","author":"S Bahrami","year":"2016","unstructured":"Bahrami, S. & Drablos, F. Gene regulation in the immediate-early response process. Adv. Biol. Regul. 62, 37\u201349 (2016).","journal-title":"Adv. Biol. Regul."},{"key":"82218_CR34","doi-asserted-by":"publisher","first-page":"325","DOI":"10.3389\/fimmu.2019.00325","volume":"10","author":"CA Jefferies","year":"2019","unstructured":"Jefferies, C. A. Regulating IRFs in IFN driven disease. Front. Immunol. 10, 325 (2019).","journal-title":"Front. Immunol."},{"issue":"2","key":"82218_CR35","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/s41385-018-0108-2","volume":"12","author":"R Guler","year":"2019","unstructured":"Guler, R. et al. Batf2 differentially regulates tissue immunopathology in Type 1 and Type 2 diseases. Mucosal Immunol. 12(2), 390\u2013402 (2019).","journal-title":"Mucosal Immunol."},{"issue":"2","key":"82218_CR36","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1546068","volume":"8","author":"J Liu","year":"2019","unstructured":"Liu, J. et al. Batf3(+) DCs and type I IFN are critical for the efficacy of neoadjuvant cancer immunotherapy. Oncoimmunology 8(2), e1546068 (2019).","journal-title":"Oncoimmunology"},{"issue":"9","key":"82218_CR37","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/s41577-020-0288-3","volume":"20","author":"J Rehwinkel","year":"2020","unstructured":"Rehwinkel, J. & Gack, M. U. RIG-I-like receptors: Their regulation and roles in RNA sensing. Nat. Rev. Immunol. 20(9), 537\u2013551 (2020).","journal-title":"Nat. Rev. Immunol."},{"issue":"4","key":"82218_CR38","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3390\/cancers10040093","volume":"10","author":"I de Garces Los Fayos Alonso","year":"2018","unstructured":"de Garces Los Fayos Alonso, I. et al. The role of activator protein-1 (AP-1) family members in CD30-positive lymphomas. Cancers (Basel) 10(4), 93 (2018).","journal-title":"Cancers (Basel)"},{"issue":"5","key":"82218_CR39","doi-asserted-by":"publisher","first-page":"3559","DOI":"10.1074\/jbc.M111.265744","volume":"287","author":"M Otero","year":"2012","unstructured":"Otero, M. et al. E74-like factor 3 (ELF3) impacts on matrix metalloproteinase 13 (MMP13) transcriptional control in articular chondrocytes under proinflammatory stress. J. Biol. Chem. 287(5), 3559\u20133572 (2012).","journal-title":"J. Biol. Chem."},{"issue":"4","key":"82218_CR40","doi-asserted-by":"publisher","first-page":"385","DOI":"10.3390\/genes11040385","volume":"11","author":"TH Kim","year":"2020","unstructured":"Kim, T. H., Kern, C. & Zhou, H. Knockout of IRF7 highlights its modulator function of host response against avian influenza virus and the involvement of MAPK and TOR signaling pathways in chicken. Genes (Basel) 11(4), 385 (2020).","journal-title":"Genes (Basel)"},{"issue":"17","key":"82218_CR41","doi-asserted-by":"publisher","first-page":"11108","DOI":"10.1074\/jbc.M115.645333","volume":"290","author":"T Li","year":"2015","unstructured":"Li, T. et al. DDIT3 and KAT2A proteins regulate TNFRSF10A and TNFRSF10B expression in endoplasmic reticulum stress-mediated apoptosis in human lung cancer cells. J. Biol. Chem. 290(17), 11108\u201311118 (2015).","journal-title":"J. Biol. Chem."},{"issue":"1","key":"82218_CR42","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s11033-018-4412-4","volume":"46","author":"AA Belanova","year":"2019","unstructured":"Belanova, A. A. et al. Effects of JUN and NFE2L2 knockdown on oxidative status and NFE2L2\/AP-1 targets expression in HeLa cells in basal conditions and upon sub-lethal hydrogen peroxide treatment. Mol. Biol. Rep. 46(1), 27\u201339 (2019).","journal-title":"Mol. Biol. Rep."},{"issue":"1","key":"82218_CR43","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2088","volume":"30","author":"H Mirzaei","year":"2020","unstructured":"Mirzaei, H. et al. The AP-1 pathway; A key regulator of cellular transformation modulated by oncogenic viruses. Rev. Med. Virol. 30(1), e2088 (2020).","journal-title":"Rev. Med. Virol."},{"issue":"1","key":"82218_CR44","doi-asserted-by":"publisher","first-page":"3450","DOI":"10.1038\/s41467-023-39122-z","volume":"14","author":"SM Gross","year":"2023","unstructured":"Gross, S. M. et al. Analysis and modeling of cancer drug responses using cell cycle phase-specific rate effects. Nat. Commun. 14(1), 3450 (2023).","journal-title":"Nat. Commun."},{"issue":"2","key":"82218_CR45","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.cell.2013.08.062","volume":"155","author":"SL Spencer","year":"2013","unstructured":"Spencer, S. L. et al. The proliferation-quiescence decision is controlled by a bifurcation in CDK2 activity at mitotic exit. Cell 155(2), 369\u2013383 (2013).","journal-title":"Cell"},{"issue":"17","key":"82218_CR46","first-page":"6540","volume":"61","author":"KE Luker","year":"2001","unstructured":"Luker, K. E. et al. Overexpression of IRF9 confers resistance to antimicrotubule agents in breast cancer cells1. Cancer Res. 61(17), 6540\u20136547 (2001).","journal-title":"Cancer Res."},{"issue":"1","key":"82218_CR47","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s41592-020-01018-x","volume":"18","author":"C Stringer","year":"2021","unstructured":"Stringer, C. et al. Cellpose: A generalist algorithm for cellular segmentation. Nat. Methods 18(1), 100\u2013106 (2021).","journal-title":"Nat. Methods"},{"issue":"1","key":"82218_CR48","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1038\/s42003-022-04208-9","volume":"5","author":"F Mohammadi","year":"2022","unstructured":"Mohammadi, F. et al. A lineage tree-based hidden Markov model quantifies cellular heterogeneity and plasticity. Commun. Biol. 5(1), 1258 (2022).","journal-title":"Commun. Biol."},{"issue":"7","key":"82218_CR49","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1016\/j.cell.2017.11.009","volume":"171","author":"AC Palmer","year":"2017","unstructured":"Palmer, A. C. & Sorger, P. K. Combination cancer therapy can confer benefit via patient-to-patient variability without drug additivity or synergy. Cell 171(7), 1678-1691 e13 (2017).","journal-title":"Cell"},{"issue":"7403","key":"82218_CR50","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nature10983","volume":"486","author":"C Curtis","year":"2012","unstructured":"Curtis, C. et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486(7403), 346\u2013352 (2012).","journal-title":"Nature"},{"issue":"10","key":"82218_CR51","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1200\/JCO.2015.63.1010","volume":"35","author":"WF Symmans","year":"2017","unstructured":"Symmans, W. F. et al. Long-term prognostic risk after neoadjuvant chemotherapy associated with residual cancer burden and breast cancer subtype. J. Clin. Oncol. 35(10), 1049\u20131060 (2017).","journal-title":"J. Clin. Oncol."},{"key":"82218_CR52","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jtbi.2014.02.025","volume":"355","author":"J Foo","year":"2014","unstructured":"Foo, J. & Michor, F. Evolution of acquired resistance to anti-cancer therapy. J. Theor. Biol. 355, 10\u201320 (2014).","journal-title":"J. Theor. Biol."},{"key":"82218_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2021.100796","volume":"59","author":"R Nussinov","year":"2021","unstructured":"Nussinov, R., Tsai, C. J. & Jang, H. Anticancer drug resistance: An update and perspective. Drug Resist. Updat. 59, 100796 (2021).","journal-title":"Drug Resist. Updat."},{"issue":"17","key":"82218_CR54","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1016\/j.devcel.2021.07.009","volume":"56","author":"DA Lukow","year":"2021","unstructured":"Lukow, D. A. et al. Chromosomal instability accelerates the evolution of resistance to anti-cancer therapies. Dev. Cell 56(17), 2427-2439 e4 (2021).","journal-title":"Dev. Cell"},{"key":"82218_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113774","volume":"155","author":"M Hashemi","year":"2022","unstructured":"Hashemi, M. et al. EMT mechanism in breast cancer metastasis and drug resistance: Revisiting molecular interactions and biological functions. Biomed. Pharmacother. 155, 113774 (2022).","journal-title":"Biomed. Pharmacother."},{"issue":"8","key":"82218_CR56","doi-asserted-by":"publisher","first-page":"2724","DOI":"10.1073\/pnas.1018854108","volume":"109","author":"LM Heiser","year":"2012","unstructured":"Heiser, L. M. et al. Subtype and pathway specific responses to anticancer compounds in breast cancer. Proc. Natl. Acad. Sci. U S A 109(8), 2724\u20132729 (2012).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"issue":"7391","key":"82218_CR57","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nature11003","volume":"483","author":"J Barretina","year":"2012","unstructured":"Barretina, J. et al. The cancer cell line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483(7391), 603\u2013607 (2012).","journal-title":"Nature"},{"issue":"Database issue","key":"82218_CR58","first-page":"D955","volume":"41","author":"W Yang","year":"2013","unstructured":"Yang, W. et al. Genomics of drug sensitivity in cancer (GDSC): A resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 41(Database issue), D955\u2013D961 (2013).","journal-title":"Nucleic Acids Res."},{"issue":"7","key":"82218_CR59","doi-asserted-by":"publisher","first-page":"3329","DOI":"10.7150\/thno.71144","volume":"12","author":"YT Chan","year":"2022","unstructured":"Chan, Y. T. et al. CRISPR-Cas9 library screening approach for anti-cancer drug discovery: Overview and perspectives. Theranostics 12(7), 3329\u20133344 (2022).","journal-title":"Theranostics"},{"issue":"19","key":"82218_CR60","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1080\/15384101.2019.1652047","volume":"18","author":"J Guillon","year":"2019","unstructured":"Guillon, J. et al. Chemotherapy-induced senescence, an adaptive mechanism driving resistance and tumor heterogeneity. Cell Cycle 18(19), 2385\u20132397 (2019).","journal-title":"Cell Cycle"},{"key":"82218_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2023.100906","volume":"42","author":"CJ Kim","year":"2023","unstructured":"Kim, C. J. et al. Nuclear morphology predicts cell survival to cisplatin chemotherapy. Neoplasia 42, 100906 (2023).","journal-title":"Neoplasia"},{"key":"82218_CR62","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/978-1-4939-7154-1_3","volume":"1636","author":"M Pargett","year":"2017","unstructured":"Pargett, M. et al. Single-cell imaging of ERK signaling using fluorescent biosensors. Methods Mol. Biol. 1636, 35\u201359 (2017).","journal-title":"Methods Mol. Biol."},{"issue":"7","key":"82218_CR63","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.cels.2023.06.005","volume":"14","author":"TS Netterfield","year":"2023","unstructured":"Netterfield, T. S. et al. Biphasic JNK-Erk signaling separates the induction and maintenance of cell senescence after DNA damage induced by topoisomerase II inhibition. Cell Syst. 14(7), 582-604 e10 (2023).","journal-title":"Cell Syst."},{"issue":"18","key":"82218_CR64","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1016\/j.devcel.2022.08.008","volume":"57","author":"P Ender","year":"2022","unstructured":"Ender, P. et al. Spatiotemporal control of ERK pulse frequency coordinates fate decisions during mammary acinar morphogenesis. Dev. Cell 57(18), 2153-2167 e6 (2022).","journal-title":"Dev. Cell"},{"issue":"7","key":"82218_CR65","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1016\/j.cell.2014.04.039","volume":"157","author":"S Regot","year":"2014","unstructured":"Regot, S. et al. High-sensitivity measurements of multiple kinase activities in live single cells. Cell 157(7), 1724\u20131734 (2014).","journal-title":"Cell"},{"issue":"21\u201322","key":"82218_CR66","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1080\/15384101.2018.1547001","volume":"17","author":"GD Grant","year":"2018","unstructured":"Grant, G. D. et al. Accurate delineation of cell cycle phase transitions in living cells with PIP-FUCCI. Cell Cycle 17(21\u201322), 2496\u20132516 (2018).","journal-title":"Cell Cycle"},{"issue":"1","key":"82218_CR67","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1038\/s41598-019-38511-z","volume":"9","author":"Y Wang","year":"2019","unstructured":"Wang, Y. et al. Real-time imaging of senescence in tumors with DNA damage. Sci. Rep. 9(1), 2102 (2019).","journal-title":"Sci. Rep."},{"issue":"1","key":"82218_CR68","doi-asserted-by":"publisher","DOI":"10.1088\/2050-6120\/aae6f8","volume":"7","author":"LA Balderstone","year":"2018","unstructured":"Balderstone, L. A. et al. Development of a fluorescence-based cellular apoptosis reporter. Methods Appl. Fluoresc. 7(1), 015001 (2018).","journal-title":"Methods Appl. Fluoresc."},{"issue":"1","key":"82218_CR69","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41576-020-0265-5","volume":"22","author":"AS Nam","year":"2021","unstructured":"Nam, A. S., Chaligne, R. & Landau, D. A. Integrating genetic and non-genetic determinants of cancer evolution by single-cell multi-omics. Nat. Rev. Genet. 22(1), 3\u201318 (2021).","journal-title":"Nat. Rev. Genet."},{"issue":"5698","key":"82218_CR70","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/277665a0","volume":"277","author":"PB Schiff","year":"1979","unstructured":"Schiff, P. B., Fant, J. & Horwitz, S. B. Promotion of microtubule assembly in vitro by taxol. Nature 277(5698), 665\u2013667 (1979).","journal-title":"Nature"},{"issue":"3","key":"82218_CR71","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","volume":"41","author":"KE de Visser","year":"2023","unstructured":"de Visser, K. E. & Joyce, J. A. The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth. Cancer Cell 41(3), 374\u2013403 (2023).","journal-title":"Cancer Cell"},{"key":"82218_CR72","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.656364","volume":"12","author":"K Khalaf","year":"2021","unstructured":"Khalaf, K. et al. Aspects of the tumor microenvironment involved in immune resistance and drug resistance. Front. Immunol. 12, 656364 (2021).","journal-title":"Front. Immunol."},{"key":"82218_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.104683","volume":"153","author":"KGK Deepak","year":"2020","unstructured":"Deepak, K. G. K. et al. Tumor microenvironment: Challenges and opportunities in targeting metastasis of triple negative breast cancer. Pharmacol. Res. 153, 104683 (2020).","journal-title":"Pharmacol. Res."},{"issue":"4","key":"82218_CR74","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.ccell.2019.08.007","volume":"36","author":"L Ma","year":"2019","unstructured":"Ma, L. et al. Tumor cell biodiversity drives microenvironmental reprogramming in liver cancer. Cancer Cell 36(4), 418-430 e6 (2019).","journal-title":"Cancer Cell"},{"issue":"8","key":"82218_CR75","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1093\/annonc\/mdw168","volume":"27","author":"JM Pitt","year":"2016","unstructured":"Pitt, J. M. et al. Targeting the tumor microenvironment: Removing obstruction to anticancer immune responses and immunotherapy. Ann. Oncol. 27(8), 1482\u20131492 (2016).","journal-title":"Ann. Oncol."},{"key":"82218_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107753","volume":"221","author":"Y Xiao","year":"2021","unstructured":"Xiao, Y. & Yu, D. Tumor microenvironment as a therapeutic target in cancer. Pharmacol. Ther. 221, 107753 (2021).","journal-title":"Pharmacol. Ther."},{"issue":"5","key":"82218_CR77","doi-asserted-by":"publisher","first-page":"eabc2511","DOI":"10.1126\/sciadv.abc2511","volume":"7","author":"J Hu","year":"2021","unstructured":"Hu, J. et al. Regulation of tumor immune suppression and cancer cell survival by CXCL1\/2 elevation in glioblastoma multiforme. Sci. Adv. 7(5), eabc2511 (2021).","journal-title":"Sci. Adv."},{"issue":"9","key":"82218_CR78","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1038\/s41416-020-1026-0","volume":"123","author":"M Yang","year":"2020","unstructured":"Yang, M. et al. Tumour-associated neutrophils orchestrate intratumoural IL-8-driven immune evasion through Jagged2 activation in ovarian cancer. Br. J. Cancer 123(9), 1404\u20131416 (2020).","journal-title":"Br. J. Cancer"},{"issue":"10","key":"82218_CR79","doi-asserted-by":"publisher","first-page":"8508","DOI":"10.1074\/jbc.M208231200","volume":"278","author":"J Heidemann","year":"2003","unstructured":"Heidemann, J. et al. Angiogenic effects of interleukin 8 (CXCL8) in human intestinal microvascular endothelial cells are mediated by CXCR2. J. Biol. Chem. 278(10), 8508\u20138515 (2003).","journal-title":"J. Biol. Chem."},{"issue":"9","key":"82218_CR80","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.3390\/cells8091007","volume":"8","author":"HS Choi","year":"2019","unstructured":"Choi, H. S. et al. Disruption of the NF-kappaB\/IL-8 signaling axis by sulconazole inhibits human breast cancer stem cell formation. Cells 8(9), 1007 (2019).","journal-title":"Cells"},{"issue":"6","key":"82218_CR81","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/ng1578","volume":"37","author":"DR Rhodes","year":"2005","unstructured":"Rhodes, D. R. et al. Mining for regulatory programs in the cancer transcriptome. Nat. Genet. 37(6), 579\u2013583 (2005).","journal-title":"Nat. Genet."},{"issue":"Suppl 1","key":"82218_CR82","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1186\/1471-2105-7-S1-S7","volume":"7","author":"AA Margolin","year":"2006","unstructured":"Margolin, A. A. et al. ARACNE: an algorithm for the reconstruction of gene regulatory networks in a mammalian cellular context. BMC Bioinform. 7(Suppl 1), S7 (2006).","journal-title":"BMC Bioinform."},{"issue":"9","key":"82218_CR83","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1038\/nbt.1563","volume":"27","author":"K Wang","year":"2009","unstructured":"Wang, K. et al. Genome-wide identification of post-translational modulators of transcription factor activity in human B cells. Nat. Biotechnol. 27(9), 829\u2013839 (2009).","journal-title":"Nat. Biotechnol."},{"issue":"1","key":"82218_CR84","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13036-023-00333-z","volume":"17","author":"AR Subbalakshmi","year":"2023","unstructured":"Subbalakshmi, A. R. et al. The ELF3 transcription factor is associated with an epithelial phenotype and represses epithelial-mesenchymal transition. J. Biol. Eng. 17(1), 17 (2023).","journal-title":"J. Biol. Eng."},{"issue":"1","key":"82218_CR85","doi-asserted-by":"publisher","first-page":"5438","DOI":"10.1038\/s41467-019-13295-y","volume":"10","author":"KSS Enfield","year":"2019","unstructured":"Enfield, K. S. S. et al. Epithelial tumor suppressor ELF3 is a lineage-specific amplified oncogene in lung adenocarcinoma. Nat. Commun. 10(1), 5438 (2019).","journal-title":"Nat. Commun."},{"issue":"6","key":"82218_CR86","doi-asserted-by":"publisher","first-page":"2596","DOI":"10.1111\/cas.15764","volume":"114","author":"M Horie","year":"2023","unstructured":"Horie, M. et al. An integrative epigenomic approach identifies ELF3 as an oncogenic regulator in ASCL1-positive neuroendocrine carcinoma. Cancer Sci. 114(6), 2596\u20132608 (2023).","journal-title":"Cancer Sci."},{"issue":"7","key":"82218_CR87","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1002\/2211-5463.13417","volume":"12","author":"LK Archer","year":"2022","unstructured":"Archer, L. K. et al. ETS transcription factor ELF3 (ESE-1) is a cell cycle regulator in benign and malignant prostate. FEBS Open Bio 12(7), 1365\u20131387 (2022).","journal-title":"FEBS Open Bio"},{"issue":"1","key":"82218_CR88","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s13046-022-02259-8","volume":"41","author":"E Fina","year":"2022","unstructured":"Fina, E. et al. Gene signatures of circulating breast cancer cell models are a source of novel molecular determinants of metastasis and improve circulating tumor cell detection in patients. J. Exp. Clin. Cancer Res. 41(1), 78 (2022).","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"4","key":"82218_CR89","doi-asserted-by":"publisher","first-page":"R41","DOI":"10.1186\/gb-2011-12-4-r41","volume":"12","author":"CH Mermel","year":"2011","unstructured":"Mermel, C. H. et al. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 12(4), R41 (2011).","journal-title":"Genome Biol."},{"issue":"1","key":"82218_CR90","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s10549-013-2408-2","volume":"138","author":"B Mesquita","year":"2013","unstructured":"Mesquita, B. et al. Frequent copy number gains at 1q21 and 1q32 are associated with overexpression of the ETS transcription factors ETV3 and ELF3 in breast cancer irrespective of molecular subtypes. Breast Cancer Res. Treat. 138(1), 37\u201345 (2013).","journal-title":"Breast Cancer Res. Treat."},{"issue":"6","key":"82218_CR91","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1002\/ijc.11023","volume":"104","author":"MJ Riemenschneider","year":"2003","unstructured":"Riemenschneider, M. J., Knobbe, C. B. & Reifenberger, G. Refined mapping of 1q32 amplicons in malignant gliomas confirms MDM4 as the main amplification target. Int. J. Cancer 104(6), 752\u2013757 (2003).","journal-title":"Int. J. Cancer"},{"issue":"9","key":"82218_CR92","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1158\/1078-0432.CCR-07-4129","volume":"14","author":"A Veerakumarasivam","year":"2008","unstructured":"Veerakumarasivam, A. et al. High-resolution array-based comparative genomic hybridization of bladder cancers identifies mouse double minute 4 (MDM4) as an amplification target exclusive of MDM2 and TP53. Clin. Cancer Res. 14(9), 2527\u20132534 (2008).","journal-title":"Clin. Cancer Res."},{"key":"82218_CR93","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.semcdb.2018.07.019","volume":"99","author":"M Francois","year":"2020","unstructured":"Francois, M., Donovan, P. & Fontaine, F. Modulating transcription factor activity: Interfering with protein-protein interaction networks. Semin. Cell Dev. Biol. 99, 12\u201319 (2020).","journal-title":"Semin. Cell Dev. Biol."},{"key":"82218_CR94","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.trsl.2019.08.005","volume":"214","author":"W Ngamcherdtrakul","year":"2019","unstructured":"Ngamcherdtrakul, W. & Yantasee, W. siRNA therapeutics for breast cancer: Recent efforts in targeting metastasis, drug resistance, and immune evasion. Transl. Res. 214, 105\u2013120 (2019).","journal-title":"Transl. Res."},{"issue":"7","key":"82218_CR95","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1158\/0008-5472.CAN-20-3108","volume":"81","author":"AJ Wolpaw","year":"2021","unstructured":"Wolpaw, A. J. et al. Drugging the \u201cUndruggable\u201d MYCN oncogenic transcription factor: Overcoming previous obstacles to impact childhood cancers. Cancer Res. 81(7), 1627\u20131632 (2021).","journal-title":"Cancer Res."},{"issue":"5","key":"82218_CR96","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/nbt.4096","volume":"36","author":"A Butler","year":"2018","unstructured":"Butler, A. et al. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat. Biotechnol. 36(5), 411\u2013420 (2018).","journal-title":"Nat. Biotechnol."},{"issue":"5","key":"82218_CR97","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nbt.3192","volume":"33","author":"R Satija","year":"2015","unstructured":"Satija, R. et al. Spatial reconstruction of single-cell gene expression data. Nat. Biotechnol. 33(5), 495\u2013502 (2015).","journal-title":"Nat. Biotechnol."},{"issue":"5","key":"82218_CR98","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu, G. et al. clusterProfiler: An R package for comparing biological themes among gene clusters. OMICS J. Integr. Biol. 16(5), 284\u2013287 (2012).","journal-title":"OMICS J. Integr. Biol."},{"issue":"2","key":"82218_CR99","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1177\/108705719900400206","volume":"4","author":"JH Zhang","year":"1999","unstructured":"Zhang, J. H., Chung, T. D. & Oldenburg, K. R. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen. 4(2), 67\u201373 (1999).","journal-title":"J. Biomol. Screen."},{"issue":"1","key":"82218_CR100","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12963-020-00217-0","volume":"18","author":"C Dudel","year":"2020","unstructured":"Dudel, C. & Myrskyl\u00e4, M. Estimating the number and length of episodes in disability using a Markov chain approach. Popul. Health Metrics 18(1), 1 (2020).","journal-title":"Popul. Health Metrics"},{"issue":"5","key":"82218_CR101","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami, E. et al. The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2(5), 401\u2013404 (2012).","journal-title":"Cancer Discov."},{"issue":"23","key":"82218_CR102","doi-asserted-by":"publisher","first-page":"3861","DOI":"10.1158\/0008-5472.CAN-23-0816","volume":"83","author":"I de Bruijn","year":"2023","unstructured":"de Bruijn, I. et al. Analysis and visualization of longitudinal genomic and clinical data from the AACR project GENIE biopharma collaborative in cBioPortal. Cancer Res. 83(23), 3861\u20133867 (2023).","journal-title":"Cancer Res."},{"issue":"269","key":"82218_CR103","doi-asserted-by":"publisher","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","volume":"6","author":"J Gao","year":"2013","unstructured":"Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal 6(269), pl1 (2013).","journal-title":"Sci. Signal"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-82218-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-82218-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-82218-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T15:38:31Z","timestamp":1738683511000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-82218-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,4]]},"references-count":103,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["82218"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-82218-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.06.04.596911","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,4]]},"assertion":[{"value":"6 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4294"}}